Botulinum Toxin Therapy in Hidradenitis Suppurativa

Part of paid clinical trials in Worcester, Massachusetts.

Sponsor
University of Massachusetts, Worcester
Study ID
NCT05403710
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Botulinum toxin — DRUG
    Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin

Study Details

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.

Key Dates

Start date
Jun 7, 2022
Status verified
Sep 2025
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
20 participants (estimated)

Arms

  • Arm: single group assignment
    men or women between the ages of 18-75 who have an established diagnosis of Hidradenitis Suppurativa

Primary Outcome Measure

Quantification and phenotyping of skin resident dendritic cell, macrophage, and T cell populations in patients before and after intralesional Botox treatment. [ Time Frame: 1-2 months after first treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Massachusetts Chan Medical SchoolWorcesterMassachusetts01605
Celia Hartigan, RN
[email protected]
774-455-4756
George Kwapong, MD
[email protected]
774-455-4756

Find similar trials in Worcester, MA

By condition
Hidradenitis suppurativa
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
University of Massachusetts Chan Medical School· Worcester, MA

Related Studies